Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Company Overview

Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company specializing in the development of proprietary oral drug delivery systems. Founded in 2006 and headquartered in Jerusalem with U.S. offices in New York, Oramed’s core focus is on transforming injectable therapies into orally administered formulations. The company was established by Dr. Nadav Kidron, who remains at the helm as Chief Executive Officer, guiding Oramed’s strategy to address chronic diseases through patient-friendly oral alternatives.

Oramed’s lead candidate, ORMD-0801, is an oral insulin capsule designed to improve glycemic control in patients with type 2 diabetes. This product has advanced through multiple Phase II clinical trials, demonstrating the potential to reduce postprandial glucose excursions and lower HbA1c levels. In addition to insulin, Oramed is advancing ORMD-0901, an oral formulation of exenatide, and a proprietary oral GLP-1 analog program aimed at obesity and metabolic syndrome, highlighting the company’s commitment to innovation in metabolic disease management.

The company operates globally, conducting clinical trials and forging strategic partnerships across North America, Europe, India and Asia. In 2021, Oramed launched Oravax Medical, a subsidiary focused on developing an oral COVID-19 vaccine; it has since expanded its pipeline to include oral vaccine candidates for influenza and other respiratory pathogens. Oramed’s collaborations with academic institutions and contract manufacturers in India and China further underscore its strategy to accelerate development and broaden market access.

Under the leadership of CEO Nadav Kidron and a management team with extensive experience in pharmaceutical R&D, regulatory affairs and commercialization, Oramed is positioned to address significant unmet needs in diabetes care and beyond. The company continues to leverage its proprietary Capsule Technology Platform to advance multiple oral therapeutic candidates, aiming to improve patient adherence and outcomes in chronic disease treatment.

Key Stats

• Today's Range: $2.10 to $2.16
• 50-Day Range: $2.09 to $2.38
• 52-Week Range: $1.82 to $3.09
• Volume: 18,717 shs
• Average Volume: 141,503 shs
• Market Capitalization: $87.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

Oramed Pharmaceuticals Stock Analysis - MarketRank™

Oramed Pharmaceuticals scored higher than 21% of companies evaluated by MarketBeat, and ranked 843rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Oramed Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.03) to ($0.19) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oramed Pharmaceuticals is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oramed Pharmaceuticals is -4.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oramed Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.19% of the float of Oramed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Oramed Pharmaceuticals has recently decreased by 11.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oramed Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Oramed Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.19% of the float of Oramed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 5.8.

Change versus previous month

Short interest in Oramed Pharmaceuticals has recently decreased by 11.91%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

Oramed Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Oramed Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

13.70% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

ORMP Stock Analysis - Frequently Asked Questions

How have ORMP shares performed this year?

Oramed Pharmaceuticals' stock was trading at $2.42 on January 1st, 2025. Since then, ORMP stock has decreased by 12.0% and is now trading at $2.13.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced its quarterly earnings data on Thursday, May, 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.03) by $0.16. The biotechnology company earned $2 million during the quarter.

Who are Oramed Pharmaceuticals' major shareholders?

Top institutional investors of Oramed Pharmaceuticals include Wealth Enhancement Advisory Services LLC (0.05%). Insiders that own company stock include Michael Rabinowitz and Nadav Kidron.
View institutional ownership trends.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oramed Pharmaceuticals investors own include TransEnterix (TRXDW), Compugen (CGEN), Sarepta Therapeutics (SRPT), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD) and Gilead Sciences (GILD).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORMP
• CIK: 1176309
• Web: www.oramed.com
• Phone: (844) 967-2633
• Fax: 972-2566-0004
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.06 million
• Net Margins: N/A
• Pretax Margin: -1,225.60%
• Return on Equity: -11.34%
• Return on Assets: -10.73%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 23.94
• Quick Ratio: 23.94

Sales & Book Value

• Annual Sales: $1.34 million
• Price / Sales: 64.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.61 per share
• Price / Book: 0.59

Miscellaneous

• Outstanding Shares: 40,850,000
• Free Float: 35,254,000
• Market Cap: $87.01 million
• Optionable: Optionable
• Beta: 1.59